MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19
C. Esslinger, S. Schmitt, M. Weber, M. Hillenbrand, J. Seidenberg, A. Zingg, C. Townsend, B. Eicher, J. Rutkauskaite, P. Riese, C. A. Guzman, K. Fischer
Abstract
Fast track microfluidic screening of the antibody repertoires of 12 convalescent COVID-19 donors comprising 2.8mio antibodies yielded MTX-COVAB, a human-derived monoclonal antibody with low picomolar neutralization IC50 of SARS-CoV-2. COVAB neutralization potency is on par with the Regeneron cocktail as demonstrated in a comparative neutralization assay. MTX-COVAB shows strong efficacy in vivo and binds to all currently identified clinically relevant variants of SARS-CoV-2. MTX-COVAB completes GMP manufacturing by the end of this year and will be tested in the clinic in March 2021.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
M. Imbrechts, W. Maes, … N. Geukens·bioRxiv·Nov 25, 2021
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 22, 2020
- Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models
W. Li, A. Drelich, … D. S. Dimitrov·bioRxiv·May 13, 2020
- A human monoclonal 1 antibody blocking SARS-CoV-2 infection
C. Wang, W. Li, … B.-J. Bosch·bioRxiv·Mar 11, 2020
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant
N. Hingankar, S. Deshpande, … J. Bhattacharya·bioRxiv·Dec 25, 2021
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
P. Brouwer, T. Caniels, … M. van Gils·bioRxiv·May 12, 2020